Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate SON-080 for the treatment of diabetic peripheral neuropathy in India.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.